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imelagatran: Oral
irect Thrombin Inhibition as
nticoagulant Therapy in Atrial Fibrillation
onathan L. Halperin, MD, FACC
ew York, New York
Atrial fibrillation (AF) causes 50,000 to 100,000 ischemic strokes annually in the U.S., most
of which could be prevented by oral anticoagulant treatment of the highest-risk patients. The
greatest barrier to such treatment is the narrow therapeutic index of the vitamin K antagonists
([VKAs]: warfarin and related coumarin derivatives), the only oral anticoagulant agents
currently available. Safe and effective treatment with the VKAs requires careful monitoring,
because they interact with many other drugs and foods, and their anticoagulant action is
unpredictable. Besides vitamin K, candidate targets for anticoagulant therapy include
thrombin, a key prothrombotic mediator. Ximelagatran, the oral direct thrombin inhibitor at
the most advanced stage of clinical development, is rapidly absorbed and bioconverted to its
active moiety, melagatran—a potent, competitive inhibitor of both free and clot-bound
thrombin. Two large clinical trials have demonstrated that fixed-dose oral ximelagatran, 36
mg twice daily, administered without coagulation monitoring, prevents stroke and systemic
embolic events in patients with nonvalvular AF as effectively as well-controlled, adjusted-dose
warfarin (international normalized ratio 2.0 to 3.0). The overall risk of bleeding was lower
with ximelagatran than warfarin, although differences in rates of major hemorrhage were not
statistically significant. Elevation of serum alanine aminotransferase levels above 3 the upper
limit of normal occurred in approximately 6% of ximelagatran-treated patients but typically
returned toward pretreatment levels without associated symptoms. In terms of preventing
thromboembolism without hemorrhage, ximelagatran may have a more favorable benefit:risk
profile than warfarin for patients with AF. (J Am Coll Cardiol 2005;45:1–9) © 2005 by the
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.09.049American College of Cardiology Foundation
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ionvalvular atrial fibrillation (AF) is associated annually
ith 50,000 to 100,000 ischemic strokes in the U.S. and
ore than a million worldwide. Among anticoagulant-naive
atients with no history of cerebrovascular events, AF
ncreases the annual risk of ischemic stroke by five-fold, to
5% (1). Because emboli from intracardiac thrombi of
iameter5 mm are large enough to occlude a major cerebral
rtery (2), AF-related cardioembolic strokes are associated with
oor functional outcomes (3), a high risk of permanent, severe
isability (4), and high early mortality (5).
Atrial fibrillation is among the most common dysrhyth-
ias seen in clinical practice. The Framingham Heart study
nvestigators reported the lifetime risk of developing AF as
pproximately one in four (6). During 18 months’ follow-up
f 1.89 million adults in California, Go et al. (7) identified
7,974 patients with diagnosed AF, a period prevalence of
.95%. Using 1995 U.S. census data, the authors estimated
he national population of patients with AF as2.3 million.
From the Mount Sinai School of Medicine, New York, New York. Dr. Halperin
s the recipient of consulting fees from AstraZeneca, L.P., as Co-Chairman of the
xecutive Steering Committee for the SPORTIF-III and -V clinical trials, which
ddress the issue of antithrombotic therapy for prevention of thromboembolism in
atients with atrial fibrillation, and Chairman of the Executive Steering Committee
or the EXPECT trial investigating this issue in the context of cardioversion.
straZeneca is the manufacturer of ximelagatran.a
Manuscript received July 19, 2004; revised manuscript August 31, 2004, accepted
eptember 6, 2004.he prevalence of AF is age-related, increasing from 1%
mong those younger than 50 years to 10% among those
lder than 80 years (1,7). As the mean age of the population
ncreases, the number of patients with AF is projected to
ouble over the next two generations (8,9), reaching 5
illion in the U.S. by 2050 (7).
Current, evidenced-based practice guidelines recommend
ntithrombotic therapy for patients with AF and additional
hromboembolic risk factors (1,10). Warfarin and other vita-
in K antagonists (VKAs) are the antithrombotic agents of
hoice for high-risk patients, as they prevent disabling cardio-
mbolic stroke far more effectively than aspirin. Intention-to-
reat (ITT) pooled analysis of five randomized primary pre-
ention trials showed that warfarin reduces stroke risk by 68%
11). In a meta-analysis of six trials, including one trial of
econdary prevention, the relative risk reduction (RRR) was
2% (12) by ITT analysis, but80% by on-treatment analysis,
hus approaching complete reversal of the excess attributable
isk (13). Nevertheless, in 1999 to 2000, VKAs were prescribed
or fewer than 50% of a sample of ambulatory high-risk
atients with AF (14).
Barriers to VKA use include high pharmacokinetic vari-
bility, a marked propensity for drug-drug and drug-food
harmacokinetic interactions, and a narrow therapeutic
ndex (15). In comparisons of warfarin with other antico-
gulants, the gradient of the dose-response curve (the Hill
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Oral Direct Thrombin Inhibition January 4, 2005:1–9oefficient [HC]) correlated with the number of coagulation
actors inhibited (Fig. 1) (16):
CWARFARIN (2 FII, FVII, FIX, FX)  3.6
HCHEPARIN (2 FII, FX)  1.8
HCMELAGATRAN (2 FII)  1.2
HCINOGATRAN (2 FII)  1.1
here the downward arrow (2) denotes decreased
oagulation-factor activity, through suppression of synthesis
warfarin) or inhibition, whether indirect (heparin) or direct
melagatran, inogatran). Among these agents, warfarin in-
ibits the greatest number of coagulation factors (four) and
xhibits the steepest dose-response curve. By contrast, the
gents with the shallowest dose-response curve, the direct
hrombin inhibitors (DTIs) melagatran and inogatran (an early
TI), inhibit a single coagulation factor (16). These findings
uggest that the narrow therapeutic index of warfarin is related
o nonselective inhibition of all four vitamin K-dependent
oagulation factors. They also suggest that rationally targeted
Abbreviations and Acronyms
AF  atrial fibrillation
DTI  direct thrombin inhibitor
INR  international normalized ratio
ITT  intention-to-treat
RRR  relative risk reduction
SEE  systemic embolic event
SPORTIF  Stroke Prevention with an ORal Thrombin
Inhibitor in Atrial Fibrillation
TIA  transient ischemic attack
VKA  vitamin K antagonist
VTE  venous thromboembolism
igure 1. Antithrombotic effect versus dose, for four different anticoagu-
ant agents, in a rat model of arterial thrombosis. The direct thrombin
nhibitors melagatran (triangles) and inogatran (squares) were adminis-
ered by continuous infusion throughout the experiment; warfarin was
dministered once daily for four consecutive days (circles); and heparin was
dministered by infusion (broken line). Warfarin (mol/kg per day);
elagatran and inogatran (mol/kg per h); heparin (kU/kg per h). Ther
lope of the dose-response curve (the Hill coefficient) for each agent is
iven in parentheses.nhibition of thrombin, a key mediator of thrombosis, might be
ssociated with a wider therapeutic index.
IMELAGATRAN
he DTI at the most advanced stage of clinical development is
imelagatran (Exanta, AstraZeneca, Charnwood, United
ingdom andMölndal, Sweden) (Fig. 2), a lipophilic molecule
hat readily penetrates cultured human intestinal epitheliocytes
17). In vitro, melagatran inhibits free and clot-bound throm-
in rapidly, potently (Ki, 2 nmol/l), and reversibly, by direct,
ompetitive binding to the catalytic site (18) (Fig. 3). In
ealthy volunteers, at least 40% to 70% of an oral ximelagatran
ose is absorbed (19) and rapidly bioconverted to the active
oiety, melagatran (17). Of more than 30,000 participants in
he ximelagatran clinical trial program, at least 17,000 have
eceived ximelagatran or melagatran, and treatment has con-
inued for at least six months in more than 6,000 patients.
revention of venous thromboembolism (VTE) after
lective hip- or knee-replacement surgery. In several
uropean countries, ximelagatran is approved for preven-
ion of VTE in patients undergoing elective hip- or knee-
eplacement surgery. A meta-analysis (20) of three Euro-
ean trials in this setting reported that subcutaneous
elagatran followed by oral ximelagatran was effective and
enerally well-tolerated. In the U.S., four trials in patients
ndergoing elective hip- or knee-replacement surgery dem-
nstrated that the efficacy of ximelagatran, 24 mg twice
aily, initiated postoperatively, was similar to that of stan-
ard therapy (21–24). Two trials reported that ximelagatran,
6 mg twice daily, was more efficacious than warfarin (target
nternational normalized ratio [INR], 2.5) in patients under-
oing elective knee-replacement surgery (24,25).
reatment and secondary prevention of acute VTE.
imelagatran 24, 36, 48, or 60 mg twice daily was compared
ith dalteparin followed by warfarin in patients with acute
ower-extremity deep venous thrombosis (26). The veno-
raphically determined course of thrombosis and the rate of
iscontinuation due to bleeding were comparable in all
reatment groups; bleeding risk did not vary with ximelagat-
an dose. A double-blind, phase III trial of secondary VTE
revention reported similar efficacy with ximelagatran, 36 mg
wice daily, and standard enoxaparin/warfarin therapy (27).
revention of thromboembolic events after myocardial
nfarction. The multinational, randomized Efficacy and
afety of the Oral DTI XimElagatran in Patients with REcent
yocardial Damage (ESTEEM) trial (n  1,883) enrolled
atients within 14 days after myocardial infarction with or
ithout ST-segment elevation (28). Patients were randomized
ither to ximelagatran in doses of 24, 36, 48, or 60 mg twice
aily, or to placebo. All received aspirin, 160 mg daily (1,10).
ver six months, ximelagatran plus aspirin was superior to
spirin alone in preventing the composite primary end point
death, nonfatal myocardial infarction, and severe recurrent
schemia), with an absolute risk reduction of 3.6% (hazard
atio, 0.76; 95% confidence interval, 0.59 to 0.98; p  0.036).
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January 4, 2005:1–9 Oral Direct Thrombin Inhibitionates of major hemorrhage were 1.8% and 0.9% (hazard ratio,
.97; 95% confidence interval, 0.80 to 4.84) in the ximelagat-
an (all doses combined) and the placebo (aspirin only) groups,
espectively. Ximelagatran was not associated with serious
dverse events. The dose associated with optimum balance
etween efficacy and safety was 24 mg twice daily. Overall, this
ose-guiding study demonstrated that, among survivors of
cute myocardial infarction, ximelagatran plus aspirin offered
etter secondary prevention than aspirin alone (28). A larger,
ore definitive trial is planned.
igure 3. Model illustrating the close fit of melagatran (a small molecule
epresented by the stick model at the center of the image) to the active
igure 2. Hypothetical schema of ximelagatran metabolism in humans.
H-melagatran, by reduction of the OH group and hydrolysis of the ethatalytic site of thrombin (a globular protein represented by the space-
lling model that dominates the image) (18). FHE STROKE PREVENTION
ITH AN ORAL THROMBIN INHIBITOR
N AF (SPORTIF) CLINICAL TRIAL PROGRAM
hase I: clinical pharmacology: SPORTIF-VI. The
pen-label, 6-day SPORTIF-VI trial compared the phar-
acodynamic and pharmacokinetic profiles of ximelagatran
n 12 patients with AF and 12 age- and gender-matched
ealthy volunteers (29,30). All participants were adminis-
ered a single 2.66-mg dose of melagatran by intravenous
nfusion on day 1 and oral ximelagatran, 36 mg twice daily,
n days 2 to 6.
HARMACODYNAMICS. Between day 1 (baseline) and day 6,
oagulation and thrombin generation were suppressed to a
imilar degree, in both study groups (Table 1). Over the
atran is formed via two intermediate compounds, ethyl-melagatran and
er group, respectively (19).
able 1. SPORTIF-VI: Pharmacodynamic Profile of Oral
imelagatran
Patients
(n  12)
Healthy Volunteers
(n  12)
ndogenous thrombin potential
(nmol/min)
Study entry 921* 1,601
Baseline (before ximelagatran
dosing on day 1)
1,271 1,336
Ximelagatran (2 h after 36 mg oral
ximelagatran on day 6)
777‡ 846†‡
ime to peak thrombin (min)
Study entry 3.48* 2.06
Baseline (day 1) 2.42*† 1.86
Ximelagatran (day 6) 4.63‡ 3.06†‡
ata are presented as the mean; n  12. Reprinted with permission from Wolzt M,
oström SL, Svensson M, et al. Pathophysiol Haemost Thromb 2003;33:68–74.
p  0.05 versus controls; †p  0.05 versus study entry; ‡p  0.05 versus day 1.
SPORTIF  Stroke Prevention with an ORal Thrombin Inhibitor in Atrial
ibrillation.
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Oral Direct Thrombin Inhibition January 4, 2005:1–9ame period, the mean proportion of platelets expressing
-selectin decreased from 7.5% to 7.0% among healthy
olunteers and from 10.9% to 9.2% among patients (29).
hese results demonstrate that ximelagatran exerts both an
nticoagulant action, associated with suppression of throm-
in generation, and a distinct antiplatelet action.
HARMACOKINETICS. In the SPORTIF-VI trial, the Cmax
or ximelagatran was 150 to 250 nmol/l after the first dose,
nd the time to Cmax (tmax) was 1 h both in patients with
F and in healthy volunteers (Table 2) (30). Melagatran
tmax, 3.0 h in patients vs. 2.9 h in healthy volunteers) was
he overwhelmingly predominant species in plasma samples
rawn 2 h or more after ximelagatran dosing. The mean
erminal elimination half-life for melagatran (t1/2, 3.5 to
.0 h) did not differ significantly between study groups, and
he bioavailability of melagatran was consistent with that
eported previously (31). The estimated renal clearance of
elagatran approximated to the calculated creatinine clear-
nce, suggesting that melagatran is eliminated primarily by
lomerular filtration. In healthy volunteers, melagatran
max was20% higher at plasma steady-state on day 6 than
fter initial ximelagatran dosing on day 2; in patients, the
orresponding increase was 30% (30). These findings
uggest that the pharmacokinetic characteristics of ximel-
gatran do not undergo clinically significantly changes
uring repeated dosing.
A population mathematical model of ximelagatran phar-
acokinetic in patients with AF was derived from pooled
esults of three SPORTIF clinical trials (II, IV, and VI), in
hich follow-up continued for up to two years. The model
redicts single-compartment disposition, with a lag-time
nd a first-order absorption-rate constant, independent of
oth treatment timing and dose (32). By covariate analysis,
he model estimates the pharmacokinetic variability of
Table 2. SPORTIF-VI: PK Characteristics of
Administration (see Table 1 for Protocol)
Melagatran PK
Parameter
Day 2—First Do
Group Geometric M
Patients
Healthy
Volunteers
AUC* (mol·h/l) 2.58 2.26
t1/2 (h) 4.0 3.5
Cmax (mol/l) 0.33 0.36
tmax (h) 3.0 2.9
CL/F (l/h) 29.5 33.7
CLR (l/h) 5.9 6.0
F (%) 21.9 20.5
Data shown are the study-group geometric means for m
study-group means, using measurements in plasma samples
permission from Wolzt M, Wollbratt M, Svensson M, et al
and AUC for day 6.
AUC  area under the concentration-time curve; CL 
Cmax  maximum plasma concentration; F  bioavailability
ORal Thrombin Inhibitor in Atrial Fibrillation; t1/2  termelagatran as23% within and15% between individuals. the interindividual variability in melagatran bioavailability
s 18%, while total variability in the area under the
oncentration-time curve is 45%. The mean t1/2 for mel-
gatran is 5 h, which permits ximelagatran dosing twice
aily. The volume of distribution correlates linearly with
ody mass (156 l at 85 kg), and melagatran clearance
orrelates with renal function. In the pooled studies, the
ioavailability of melagatran was not significantly altered by
oncomitant administration of angiotensin-converting en-
yme inhibitors, beta-blockers, loop diuretics, verapamil, or
ihydropyridine derivatives.
Similarly, studies in healthy volunteers (33) found that
he pharmacokinetic profile of ximelagatran was not altered
y concomitant administration of diclofenac, nifedipine, diaz-
pam (34), aspirin (35), digoxin (36), or atorvastatin (37). A
harmacokinetic interaction between ximelagatran and eryth-
omycin was associated with only a minor change in activated
artial-thromboplastin time (38). Although ximelagatran me-
abolism appears independent of the P450 enzyme system (35),
he mechanism of interaction with erythromycin is under
nvestigation. The pharmacokinetic profile of ximelagatran is
ot significantly influenced by age, gender (39), ethnicity (40),
besity (41), or intake of food (42) or alcohol (43).
hase II tolerability and general safety: SPORTIF-II
nd -IV. The tolerability and safety of long-term ximel-
gatran therapy in patients with AF were evaluated in the
PORTIF-II trial, a 12-week dose-guiding trial (44) at 37
enters in 11 countries. Patients with AF and at least one
dditional thromboembolic risk factor were randomized to
ither fixed-dose ximelagatran, 20, 40, or 60 mg twice daily
ithout coagulation monitoring, or adjusted-dose warfarin
target INR, 2.0 to 3.0). As the inclusion criteria for the
PORTIF-II trial and for the subsequent phase III
PORTIF-III and -V trials were based on current indica-
gatran After Oral Ximelagatran
mg Oral Ximelagatran
Day 6—Last Dose
Group Geometric Mean
Ratio Patients
Healthy
Volunteers Ratio
1.14 2.87 2.53 1.13
1.14 4.2 3.7 1.12
0.92 0.43 0.42 1.03
1.05 2.9 2.7 1.06
0.87 26.5 30.0 0.88
0.98 5.9 6.2 0.95
1.1 24.3 23.0 1.1
an PK parameters, and the between-group ratios of the
after the first and last ximelagatran doses. Reprinted with
Clin Pharmacol 2003;59:537–43. *AUC is given for day 2
creatinine clearance; CLR  renal clearance of melagatran;
pharmacokinetic; SPORTIF  Stroke Prevention with an
imination half-life; tmax  time to reach Cmax.Mela
36-
se
ean
elagatr
drawn
. Eur J
renalions for long-term anticoagulation in patients with AF,
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January 4, 2005:1–9 Oral Direct Thrombin Inhibitionhese SPORTIF study populations broadly resembled those
n earlier placebo-controlled trials of warfarin. The primary
nd point was the number of thromboembolic and major
leeding events.
Patients completing the SPORTIF-II trial were eligible
or its open-label extension, SPORTIF-IV, with follow-up
ontinuing up to five years. Patients in the SPORTIF-IV
rial received the originally randomized antithrombotic
gent, but all patients assigned to ximelagatran coalesced to
dose of 36 mg twice daily. Interim analysis was conducted
wo years after randomization (45). In the warfarin group
n  67), the proportion of patients with INR values in the
arget range increased from 34% at entry (reflecting previous
arfarin treatment) to 57% at SPORTIF-II study comple-
ion (12 weeks after randomization). Mean adherence to
imelagatran treatment (n  187), estimated by tablet
ounts, was 100%, 96%, and 98% in the 20-, 40-, and
0-mg dose groups, respectively.
Four nonfatal primary end point events occurred in the
PORTIF-II trial: one ischemic stroke and one transient
schemic attack (TIA) in the ximelagatran group and two
IAs in the warfarin group (44). One major hemorrhage
ccurred in a warfarin-treated patient, but none in patients
andomized to ximelagatran. In both treatment groups,
50% of patients reported adverse events during the study;
he incidence of most adverse events did not differ signifi-
antly between groups. Serum alanine aminotransferase
levations above 3 the upper limit of normal (ULN)
3), however, were reported only among ximelagatran-
reated patients (8 of 187  4.3%). In all eight of these
atients, serum alanine aminotransferase levels returned to
ormal whether treatment was continued (five patients) or
nterrupted (three patients) (44).
In the SPORTIF-IV interim analysis, two years after
andomization, two nonfatal ischemic strokes had occurred
uring 231 ximelagatran treatment-years (0.9% per year),
ompared with two fatal hemorrhagic strokes during 76
arfarin treatment-years (2.6% per year). For TIAs, the
ates were 0.4% per year and 2.6% per year, respectively
45). Rates of major bleeding were 0.9% per year (ximel-
gatran) versus 2.6% per year (warfarin). Five patients died,
ncluding the two warfarin-treated patients with hemor-
hagic strokes; of three deaths in the ximelagatran group,
one was attributed to study treatment. Twelve patients had
lanine aminotransferase elevations 3 ULN on ximel-
gatran, but alanine aminotransferase level returned to
ormal in all 12 (8 who continued and 4 who discontinued
reatment) (45).
hase III: efficacy—SPORTIF-III and -V. Two ran-
omized phase III trials (combined, n  7,000) evaluated
he efficacy of ximelagatran in patients with AF at elevated
hromboembolic risk: SPORTIF-III, at 259 centers in
urope, Asia, and Australasia, and SPORTIF-V, at 409
enters in North America (46). The protocols differed only
s regards treatment blinding: open-label administration of
imelagatran or warfarin in the SPORTIF-III trial, and rouble-blind anticoagulation in the SPORTIF-V trial.
ooled analysis of the results from both trials was prespeci-
ed to assess heterogeneity, compare the effects of the
nticoagulants on events occurring at low frequencies, and
xamine patient subgroups.
Given the proven efficacy of the VKAs in patients with
F, a placebo would have been unethical, and an active-
ontrol design was required; the SPORTIF-III and -V
rials, therefore, tested the noninferiority, within a mar-
in of 2% per year, of ximelagatran relative to adjusted-
ose warfarin (46), based upon the hypothesis that
xed-dose ximelagatran, 36 mg twice daily, without
oagulation monitoring, prevents all stroke (ischemic or
emorrhagic) and systemic embolic events (SEEs) at least
s effectively as well-adjusted warfarin (target INR, 2.0 to
.0). In the combined study population, the mean age was
1.6 years, 69% were male, and 75% had at least two
hromboembolic risk factors beyond AF. Treatment al-
ocation was balanced according to aspirin therapy at
ntry and history of stroke or TIA. In both trials, local
valuation of primary end point events was masked, and
ll such events were independently assessed by a Central
vent Adjudication Committee to reduce bias, particu-
arly in the open-label trial (47).
At study entry, typical patients in the SPORTIF-III trial
n 3,407) were elderly, hypertensive, high-risk white men
olerating warfarin anticoagulation (46,47). After random-
zation, the demographic and risk-factor profiles of the
reatment groups were similar. There were 1,158 men (68%)
n the ximelagatran group (n  1,704) and 1,196 (70%) in
he warfarin group (n  1,703). Mean age was 70.1 years
standard deviation, 8.6) in the ximelagatran group, com-
ared with 70.3 years (standard deviation, 8.6) in the
arfarin group. In both groups, 88% of patients were white,
nd 34% were 75 years old. Thromboembolic risk factors,
uch as left ventricular dysfunction, diabetes mellitus, and
ypertension, were distributed evenly; mean systolic blood
ressure was 139 mm Hg in both groups. Multiple risk
actors were present in 70% and 68% of patients in the
imelagatran and warfarin groups, respectively. Use of
spirin at entry was 20% in the ximelagatran group and 21%
n the warfarin group. Continued use of aspirin, in doses of
p to 100 mg per day in addition to randomized anticoag-
lant therapy was permitted for patients with concomitant
oronary disease, in keeping with guidelines (1,10).
The mean follow-up in the SPORTIF-III trial was 17.4
onths; INR values in patients assigned to warfarin (mean,
.5  0.7) were within the target range (2.0 to 3.0) for 66%
f the entire duration of exposure and within the extended
ange of 1.8 to 3.2 for 81%. Adherence to ximelagatran
herapy (tablet counts) was 94% (47).
By ITT analysis, primary end point events occurred in 40
atients randomized to ximelagatran, during 2,446 patient-
ears at risk (1.64% per patient-year) (47). Thirty-two had
schemic stroke (1.3% per patient-year), four had hemor-
hagic stroke (0.2% per patient-year), and four had SEE
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Oral Direct Thrombin Inhibition January 4, 2005:1–90.2% per patient-year). Primary events occurred in 56
atients randomized to warfarin, during 2,440 patient-years
t risk (2.29% per patient-year). Forty-six had an ischemic
troke (1.9% per patient-year), nine had hemorrhagic stroke
0.4% per patient-year), and two had SEE (0.1% per
atient-year). Compared with warfarin, ximelagatran was
ssociated with an absolute risk reduction of 0.65% (95%
onfidence interval, 0.1 to 1.4; p  0.1) (Table 3, Fig. 4)
47,48), which met the predefined criterion for noninferi-
rity (2% per year) relative to warfarin. The RRR was 29%
95% confidence interval 6.5 to 52). Kaplan-Meier curves
able 3. Incidence of Primary and Secondary Events According t
Ev
Xime
(n 
rimary events (ITT) 40 (
Ischemic stroke 32 (
Hemorrhagic stroke 4 (
SEE 4 (
rimary events (OT) 29 (
rimary event or death (ITT) 103 (
ortality‡ 78 (
atal stroke or fatal SEE 12 (
atal stroke 10 (
atal hemorrhagic stroke 3 (
atal or disabling stroke§ 15 (
onfatal disabling stroke 5 (
IA 23 (
I 24 (
omposite of mortality, stroke, SEE, and MI (OT) 96 (
omposite of ischemic stroke, SEE, and TIA (OT) 48 (
ajor bleeding (OT) 29 (
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January 4, 2005:1–9 Oral Direct Thrombin Inhibitionroup, 3%; warfarin group, 4%. Only 138 patients (4.1%)
ithdrew from the study for reasons other than death, and
he rate of premature, permanent discontinuation was lower
han in earlier studies of warfarin. Efficacy was consistent
cross all predefined subgroups, irrespective of risk factors.
Treatment groups did not differ significantly with respect
o all-cause mortality (3.2% per year), fatal or nonfatal
isabling stroke, or composite secondary end points (47).
ates of bleeding (major plus minor, the latter including
urpura, epistaxis, occult fecal hemoglobin, and microscopic
ematuria) (47) were 25.8% per year with ximelagatran (478
atients) versus 29.8% per year with warfarin (547 pa-
ients)—an RRR of 14% (95% confidence interval, 4% to
2%; p  0.0065) favoring ximelagatran (47). In both
roups, total bleeding rates among patients with creatinine
learance 80 ml/min (ximelagatran, 31% per year; warfa-
in, 29% per year) were similar to those with better renal
unction (ximelagatran, 20% per year; warfarin, 32% per
ear) (47). Hemorrhagic stroke, fatal hemorrhagic stroke,
ther major bleeding, and study drug discontinuation re-
ated to major bleeding occurred at similar rates in the two
roups (47).
During the trial, concomitant aspirin use was more
requent in the ximelagatran group (337 of 1,704; 20%) than
he warfarin group (290 of 1,703; 17%; p  0.042)
47,49,50). Among patients taking aspirin, 14 primary
vents occurred during 477 patient-years (2.94% per year) in
he ximelagatran group versus 16 events during 399 patient-
ears (4.01% per year) in the warfarin group, an absolute risk
eduction of 1.08% per year (95% confidence interval,
3.57 to 1.42). Among patients not taking aspirin, 26
rimary events occurred during 1,969 patient-years (1.32%
er year) with ximelagatran versus 40 events during 2,042
atient-years (1.96% per year) with warfarin, an absolute
isk reduction of 0.64% per year (95% confidence interval,
1.43 to 0.15). Statistical testing did not suggest any
ignificant correlation between study drug and concomitant
se of aspirin (p  0.85). The higher rate of primary events
mong patients taking aspirin may reflect a greater intrinsic
isk in this patient subgroup (50).
Adverse events were reported in 1,472 patients (87%) in
he ximelagatran group, compared with 1,452 patients
85%; p  0.228) in the warfarin group. As in the
PORTIF-II and -IV trials, between-group differences in
he frequency of particular adverse events were not signifi-
ant, except for serum alanine aminotransferase elevations.
levations 3 ULN developed in 107 patients (6%) in
he ximelagatran group versus 14 (1%; p  0.0001) with
arfarin. Typically, these began one to six months after
nitiation of treatment, were not associated with specific
ymptoms, and returned toward baseline without clinical
equelae whether therapy was continued (59 patients) or
iscontinued (48 patients).
The composite rate of death, primary events, and major
leeding during treatment was used as a measure of net
linical benefit in an exploratory, post-hoc analysis. The nomposite rate was 4.6% per year with ximelagatran (104
vents) versus 6.1% per year with warfarin (143 events),
RR 25% (95% confidence interval, 4 to 42; p  0.019)
avoring ximelagatran (47).
In the double-blind SPORTIF-V trial (n  3,922),
rimary end point events occurred in 88 patients during
,405 patient-years of exposure (mean, 20 months per
atient) (51). By ITT analysis, rates of primary events were
.2% per year (warfarin) versus 1.6% per year (ximelagat-
an), absolute risk reduction 0.4% per year (95% confidence
nterval, 0.13% to 1.03% per year; p 0.13). This result met
he prespecified criterion for noninferiority of ximelagatran
elative to warfarin, confirming the principal result of the
PORTIF-III trial.
By on-treatment analysis, the absolute risk reduction for
rimary end point events was 0.55% per year (95% confi-
ence interval, 0.06 to 16; p  0.089). For the composite
f primary events and all-cause mortality, the difference was
ot significant (0.10% per year; 95% confidence interval,
0.97% to 1.18% per year; p  0.86). Rates of disabling or
atal stroke did not differ between groups.
As in the SPORTIF-III trial, the quality of warfarin
nticoagulation in the SPORTIF-V trial was better than in
arlier trials (47,51,52), and far better than in usual practice.
or warfarin-treated patients, the INR (mean, 2.4  0.8)
as within the target range (2.0 to 3.0) 68% of the time and
ithin the extended range (1.8 to 3.2) 83% of the time. The
ombined rate of bleeding (major plus minor) was signifi-
antly lower with ximelagatran (37% per year) than with
arfarin (47% per year; p  0.0001). There were no
ignificant between-group differences in the rates of hem-
rrhagic stroke or major bleeding. Within the first six
onths of treatment, alanine aminotransferase elevation
3 ULN developed in 6.0% versus 0.8% (p  0.001) of
atients with ximelagatran and warfarin, respectively. Typ-
cally, elevations were not associated with specific symp-
oms, and alanine aminotransferase returned toward the
retreatment baseline, whether treatment was continued or
iscontinued. One 80-year-old patient, however, developed
atal gastrointestinal bleeding during corticosteroid therapy
or hepatitis associated with ximelagatran.
The prespecified pooled analysis of the SPORTIF-III
nd -V trials (51) encompassed a total exposure of 11,346
atient-years (mean, 18.5 months). Treatment groups did
ot differ with respect to rates of primary events or strokes
f presumed cardioembolic or noncardioembolic origin. In
he ITT populations, the primary event rates were 1.62%
er year versus 1.65% per year in the ximelagatran and
arfarin groups, respectively, absolute risk reduction with
imelagatran of 0.03% per year (95% confidence interval,
0.44% to 0.50% per year; p  0.941). In the subpopula-
ion with a history of stroke or TIA, primary event rates
ere 2.83% (ximelagatran) versus 3.27% (warfarin), an
bsolute risk reduction of 0.44% per year (95% confidence
nterval,0.98 to 1.86; p 0.625). Ischemic stroke (mostly
oncardioembolic) occurred at rates of 0.75% per year
(
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Oral Direct Thrombin Inhibition January 4, 2005:1–9ximelagatran) versus 0.92% per year (warfarin). Rates of
ardioembolic stroke were low: 0.62% per year (ximelagat-
an) versus 0.53% per year (warfarin). The annual incidence
f bleeding (minor plus major) was lower with ximelagatran
32%) than warfarin (39%; p  0.0001). The rate of
ntracranial hemorrhage was 0.11% per year with ximelagat-
an versus 0.20% per year with warfarin (51). Aspirin was
sed concomitantly by 22.7% and 17.2% of patients with
nd without a history of stroke, respectively.
ONCLUSIONS
otentially fatal or disabling cardioembolic stroke continues
o threaten a large proportion of patients with AF, chiefly
ecause VKA oral anticoagulation is used in fewer than half
f eligible patients despite numerous trials demonstrating
he efficacy of warfarin. Recognized barriers to wider use of
KAs include their unpredictable anticoagulant action,
harmacokinetic variability, and propensity for drug-drug
nd drug-food pharmacokinetic interactions, as well as the
ngoing need for regular therapeutic monitoring. Para-
ount among the limitations of the VKAs is a narrow
herapeutic index that reflects nonselective inhibition of
ultiple coagulation factors. In this context, selective tar-
eting of a single prothrombotic mediator has emerged as
he key therapeutic principle guiding the rational design of
ext-generation antithrombotic agents.
The oral DTI ximelagatran has received regulatory ap-
roval in various European countries for the prevention of
hromboembolic events in patients undergoing elective total
ip- or total knee-replacement surgery, but the compound
as not gained regulatory approval in the U.S. for any
ndication to date. In the SPORTIF-III and -V trials, two
arge phase III trials with a combined study population of
ore than 7,000 patients with nonvalvular AF, oral ximel-
gatran, 36 mg twice daily, administered at a fixed dose
ithout coagulation monitoring, prevented stroke as effec-
ively as well-controlled warfarin (INR 2.0 to 3.0), without
ncreased bleeding (47,51,52). Serum transaminase levels
ncreased in a small percentage of patients during the early
onths of ximelagatran treatment but further studies are
eeded to establish the frequency or occurence of more
erious liver disease. Nevertheless, by eliminating both
oagulation monitoring and dose adjustment, ximelagatran
as the potential to encourage the use of oral anticoagula-
ion in a larger proportion of the eligible, at-risk population
f patients with AF (53–55). Were ximelagatran approved
or oral anticoagulation in this setting, then the guidelines
or management of patients with AF would need to be
evised (56).
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